Investigational drug · Phase 3
of Physician's Choice
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
325
Any phase or sponsor naming "of Physician's Choice"
First trial start
2023
Dec 5, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "of Physician's Choice", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
- Metastatic Breast Cancer
- Breast Neoplasm
- Breast Cancer Metastatic
- End Stage Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "of Physician's Choice" as an intervention, largest first.
Jaseng Hospital of Korean MedicineAcademic, hospital or other
NCT02257723 · 100,000 participants (planned) · Start Jan 2012 · Primary completion Dec 2030
Drug: Herbal medicine · For: Low Back Pain; Neck Pain; Knee Pain and 3 more
Sites: Seoul, South Korea
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
Jaseng Hospital of Korean MedicineAcademic, hospital or other
NCT02299739 · 6,894 participants · Start Dec 2005 · Primary completion Dec 2013
Drug: Herbal medicine · For: Drug-Induced Liver Injury; Musculoskeletal Diseases
Sites: Seoul, South Korea
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
- De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07153757 · 2,934 participants (planned) · Start Sep 1, 2025 · Primary completion Sep 1, 2033
Drug: Endocrine Therapy of Physician's Choice · For: Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Sites: Shanghai, China
The League of Clinical Research, RussiaAcademic, hospital or other
NCT04863274 · 2,912 participants · Start Jun 21, 2018 · Primary completion Oct 15, 2020
Drug: atorvastatin · For: Lipid Metabolism Disorders
Sites: Moscow, Russia
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer(Cinnamon)Pivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT07432178 · 2,288 participants (planned) · Start Apr 3, 2026 · Primary completion Mar 31, 2031
Drug: Dalpiciclib+AI ± OFS; TC (Docetaxel + Cyclophosphamide) × 4 cycles- endocrine therapy · For: Breast Cancer
Sites: Shanghai, China
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT07391774 · 1,978 participants (planned) · Start Aug 10, 2026 · Primary completion Jul 31, 2029
Drug: Anastrozole; Chemotherapy and 3 more · For: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8 and 2 more
Sites: Jonesboro, Arkansas; Auburn, California; Berkeley, California · 264 sites in all
- Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant AbemaciclibPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT06341621 · 1,900 participants (planned) · Start Apr 2, 2024 · Primary completion Feb 25, 2027
Drug: 3-year abemaciclib without chemo; treatment of physician's choice · For: Breast Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- First-line Gemcitabine Versus Treatment of Physician's Choice for Metastatic Breast Cancer: A Prospective Cohort Study.
Yamamoto S, Narui K, Ishikawa T, et al. · Anticancer Res 2021
- High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
Miyoshi Y, Yoshimura Y, Saito K, et al. · Breast Cancer 2020
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.